Home・Elenco Azioni・Alvotech SA

Alvotech SA

Aperta

SettoreSettore sanitario

4.05 -0.74

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.98

Massimo

4.13

Metriche Chiave
By Trading Economics
Entrata	110M 1M
Vendite	-60M 106M
P/E Media del settore	42.4 57.002
EPS	-0.09
Margine di Profitto	0.973
Dipendenti	1,279
EBITDA	167M 52M

Raccomandazioni
By TipRanks
Raccomandazioni	Vendi
Previsioni per 12 mesi	-2.2% downside

Dividendi
By Acuity
Utili prossimi	19 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	261M 1.3B
Apertura precedente	4.79
Chiusura precedente	4.05

Notizie sul Sentiment di mercato

By Acuity

40%

60%

134 / 340 Classifica in Healthcare

Alvotech SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 ago 2026, 20:06 UTC

Alvotech SA shares are higher during Thursday's session, continuing an upward trend since Wednesday's close, trading above its 20-day moving average.

12 ago 2026, 19:31 UTC

Alvotech SA shares are trading higher, reflecting market optimism after recent inflation data showed core CPI aligned with forecasts. No specific company news was identified.

11 ago 2026, 19:26 UTC

News

Alvotech's Reykjavik facility receives Voluntary Action Indicated status from the FDA, allowing advancement of multiple Biologics License Applications. Shares are trading higher.

10 ago 2026, 20:06 UTC

News

Alvotech SA will release its financial results for the first half of 2026 on August 19, after the U.S. market close. Shares are little changed.

6 ago 2026, 20:06 UTC

Alvotech SA shares are higher today, trading above their 20-day moving average and near the upper end of their one-month range. No specific news was identified.

5 ago 2026, 19:56 UTC

Alvotech SA shares are lower during Wednesday's session, continuing a decline since Tuesday's close amid broader market trends and falling oil prices.

4 ago 2026, 19:52 UTC

Alvotech SA shares are higher today, supported by declining crude oil prices easing inflation concerns. The stock remains above its 20-day moving average.

3 ago 2026, 19:51 UTC

Alvotech SA shares are lower today, reflecting a sharp decline despite a brief rebound earlier in the session. No specific news was identified for the drop.

31 lug 2026, 21:02 UTC

Alvotech SA shares declined in after-market trading, reversing six days of gains. No specific news was identified to explain the price movement.

30 lug 2026, 20:10 UTC

Alvotech SA shares are higher during Thursday's session, reflecting broader market movements amid mixed economic signals and maintaining a position above the 20-day moving average.

29 lug 2026, 19:04 UTC

News

Social Media

Alvotech SA's FDA inspection results in a Voluntary Action Indicated classification. Shares are trading higher as the company advances its biosimilar pipeline.

28 lug 2026, 19:56 UTC

Alvotech SA shares are higher today, reaching a high of 6.17%. The stock remains below its 20-day moving average with no specific news identified.

27 lug 2026, 19:31 UTC

Alvotech SA shares are higher today, rebounding from an earlier session low. This follows a positive trend since Friday's close amid declining oil prices.

24 lug 2026, 19:51 UTC

Alvotech SA shares are lower today, continuing a trend of weakness amid broader market pressures and three consecutive lower daily closes.

22 lug 2026, 18:31 UTC

Alvotech SA shares are lower, continuing a decline since Tuesday. Broader market sentiment is impacted by geopolitical tensions and rising crude oil prices.

21 lug 2026, 19:16 UTC

Alvotech SA shares are higher during Tuesday's session amid a broader market recovery, driven by renewed interest in AI stocks and upcoming tech earnings.

20 lug 2026, 19:31 UTC

Alvotech SA shares are lower today, with no specific news identified. Broader market weakness includes a decline in the US 10Y Treasury Bond index.

Confronto tra pari

Modifica del prezzo

Alvotech SA Previsione

Obiettivo di Prezzo

By TipRanks

-2.2% in calo

Previsioni per 12 mesi

Media 4 USD -2.2%

Alto 4 USD

Basso 4 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Alvotech SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Vendi

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Alvotech SA - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

134 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.